Pay in 4 interest-free payments of $6.46 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
Zhao P, Liang YL, Belousoff MJ, et al
Evidence from the SURPASS phase III clinical trial program has consistently demonstrated the superior metabolic efficacy of tirzepatide compared with currently available GLP-1 receptor agonists, such as semaglutide
Functional strengthsuch as the ability to lift objects, move efficiently, and perform daily tasksimpacts quality of life and can reduce the risk of falls, frailty, and injury
Table 1 presents the baseline characteristics of the GLP-1 and non-GLP-1 RA cohorts
US$ 25.66
US$ 24.78
US$ 27.88
:max_bytes(150000):strip_icc()/VWHealth-When-can-you-expect-a-GLP-1-plateau-edit-2-0d8af747d2004ea18f48ef96fe6c5284.jpg)
US$ 23.21
US$ 22.65
